Biofortuna, a UK based molecular diagnostics company specialising in its own proprietary freeze-dried expertise and cryo-preservatives, has launched a new contract development and production service. The aim of the service is to develop stabilised molecular diagnostics products to gain an additional competitive advantage.

The services range from the conversion of a currently available PCR test through to the management of a full development and production project.

The freeze-dried product, including taq polymerase, is not only stable at ambient temperatures for up to 16 months, but has an instantly soluble freeze dried pellet avoiding the need for vortexing or pipette mixing. Biofortuna’s freeze-dried solution results in one step protocols where the end user is only required to add sample DNA prior to amplification and detection.

Dr Simon Douglas, Biofortuna’s CEO said: “We are delighted to be launching this service and allowing companies to access our high level of design and production expertise as well as our proprietary freeze-dried technology. This service will allow companies to create simple stable and long lasting diagnostic kits that will differentiate their products in the market place whilst enhancing speed and reproducibility in laboratory testing.”

He added: “This builds on our current range of CE marked freeze dried stabilised HLA kits which are distributed globally.”